Cart 0

ADVISING GENUINE IMPACT

OUR FOCUS IS ON EARLY STAGE SMES THAT NEED ASSISTANCE TO COMMERCIALISE FASTER, DEVELOP IP STRATEGICALLY AND FUNDRAISE APPROPRIATELY. OUR METHODS HAVE RESULTED IN IMPACTFUL RETURNS

 

ACCELERIS VALUE ADD

 
 
AdobeStock_185369586.jpeg

MAKING ENERGY CREATION & STORAGE AFFORDABLE FOR ALL

Power Roll

Power Roll have developed and proven a unique architecture utilising micro-groove structures to create a variety of disruptive devices. The company boasts an extensive patent portfolio and multiple high-value advantages over existing global technologies.

Acceleris has advised the company since 2016, introducing private investors to the business alongside ongoing corporate finance support.

AMR-21.11.17-0810-1-uai-2880x1920.jpg

LEADING THE FIGHT AGAINST THE GLOBAL THREAT ANTI-MICROBIAL RESISTANCE

AMR Centre

The AMR Centre is a joint private-public initiative to support/accelerate the development of new antibiotics and diagnostics through a fully integrated development capability, offering translational R&D from pre-clinical hits through to clinical proof of concept.

Acceleris has advised the company prior to incorporation, introducing private investors to the business alongside ongoing corporate finance support. 

AdobeStock_85250554.jpeg

IMPROVING THE QUALITY OF LIFE FOR ALLERGY SUFFERERS

Reacta

Reacta are commercialising the work of the world leaders in allergy diagnostics in order to significantly improve the diagnosis and management of food allergy. The company is generating significant revenues internationally and is working to expand into a new manufacturing facility.

Acceleris has advised the company from pre-revenue and has introduced multiple rounds of private funding as well as sitting on the board of directors

metronet-siklu-ceragon.jpg

INTRODUCING LAST MILE WIRELESS FIBRE LEASE LINE

M247 (previously Metronet UK)

M247 are an internet service provider supplying lighting fast internet connectivity to the likes of AO.com and onthebeach.com. Founded in 2003, the company has grown rapidly to a number of worldwide offices.

Acceleris advised Metronet from pre start-up advising on numerous rounds of early-stage EIS funding. The company enjoyed consistent growth which resulted in two years of dividend payments to Acceleris investors prior to a private equity exit in 2013.

image.png

ELIMINATING TOXICITY IN CANCER THERAPEUTICS

BiVictriX Therapeutics

As new oncology therapeutics progress through the clinic and on to the market, toxicities generated due to the expression of the targets on healthy tissues represent a key concern linked with significant long term morbidities and dramatically reduce the effectiveness of the therapies. The company’s innovative Bi-Cygni® Dual Targeting platform is designed to combat toxicity in cancer treatment.

Acceleris have supported the company from incorporation, advising on the original spin-out then assisting in the introduction of leading investment institutions alongside private SEIS investors. The creativity of this deal was nominated for numerous industry awards.

image.png

DRIVING INNOVATION & PROGRESS WITH WORLD CLASS CHEMISTRY

Apex Molecular

Apex Molecular is a Contract Research Organisation providing specialist services for the pharmaceutical, biotechnology (life sciences) and applied chemical sectors.

The company provides fast, reliable, cost effective delivery of laboratory scale chemistry development services for the life sciences and wider chemical sectors.

Acceleris advised the founders pre incorporation and have since introduced multiple rounds of funding and continue to assist at board level in a company secretarial position. Acceleris also provide accounting services to the business.

 
 
 
image.png

PIONEERING TRANSFORMATIONAL DRUG DISCOVERY AND DEVELOPMENT

Redx Pharma

Redx Pharma Plc is a drug discovery and development business creating high value cancer and fibrosis therapeutics. Redx Pharma uses its proven drug discovery expertise to generate development candidates that it will take into the clinic and then partner. 

Acceleris advised the founders of Redx from pre incorporation, introducing multiple levels of private and institutional funding to rapidly grow the organisation. Following five years of progress, Acceleris advised on the pre-IPO and IPO on to the AIM market of the London Stock Exchange. 

image.png

INNOVATIVE CROP PROTECTION CHEMISTRY FOR A GLOBAL MARKET

Redag Crop Protection

Redag Crop brings cost effective innovation to the agrochemical sector through targeting specific improvements to existing products and late-stage research. The company enables customers to make a head start in taking novel active ingredients to market, complimenting or avoiding the need for discovery infrastructure. 

Acceleris advised on the original spin-out from Redx Pharma Plc. and has introduced private and institutional funding. Acceleris also advised on the partial sale to Globachem NV, providing the business with working capital and a partial return for shareholders. 

image.png

SCIENTIFICALLY DRIVEN NUTRITION & MEAL PLANNING

Bite Club Kitchen

Bite Club is a “healthy food” business whose products have been developed based on scientific validation.

The business model for Bite Club also enjoys a point of difference in the market place through an innovative approach and the use of an interactive mobile application (“app”) in the social media space. 

Acceleris has assisted the company in two rounds of private funding and have been directly involved in ongoing strategy of the business to achieve the required growth. 

CONTACT US

Acceleris provide Corporate Finance Advisory Services to SME’s and are authorised by the Financial Conduct Authority.

acceleris-banner.png